New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:07 EDTINSYInsys receives FDA orphan drug designation for pharmaceutical cannabidiol
Insys Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its pharmaceutical cannabidiol for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. The company said, "We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application for CBD in 2H14."
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information
November 12, 2014
10:00 EDTINSYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTINSYInsys Therapeutics downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded Insys to Perform from Outperform. The firm believes that the stock values Suybsys fairly at current levels, while the company's nearest-term pipeline opportunities will likely not materialize until 2016.
07:55 EDTINSYInsys Therapeutics downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
November 11, 2014
06:52 EDTINSYInsys Therapeutics reports Q3 non-GAAP EPS 63c, consensus 29c
Subscribe for More Information
November 10, 2014
15:26 EDTINSYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings DR Horton (DHI), consensus 48c; Sabre (SABR), consensus 26c; AECOM Technology (ACM), consensus 82c; CST Brands (CST), consensus 57c; Qiwi plc (QIWI), consensus 36c; INSYS Therapeutics (INSY), consensus 29c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use